Evidence map›Paper›PMID 25505557›Full record

ArticlePharmacology research & perspectives2013

Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models.

Alykhan S Motani, Jian Luo, Lingming Liang, Jeffrey T Mihalic, Xiaoqi Chen, Liang Tang, Leping Li, Juan Jaen, Jin-Long Chen, Kang Dai

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. A Straightforward Synthesis of FunctionalizedMolecules (Basel, Switzerland) · 2019
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alykhan S MotaniDiscovery Research, Amgen, Inc.
Jian LuoDiscovery Research, Amgen, Inc.
Lingming LiangDiscovery Research, Amgen, Inc.
Jeffrey T MihalicDiscovery Research, Amgen, Inc.
Xiaoqi ChenDiscovery Research, Amgen, Inc.
Liang TangDiscovery Research, Amgen, Inc.
Leping LiDiscovery Research, Amgen, Inc.
Juan JaenDiscovery Research, Amgen, Inc.
Jin-Long ChenDiscovery Research, Amgen, Inc.
Kang DaiDiscovery Research, Amgen, Inc.
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanin-concentrating hormone (MCH) regulates food intake through activation of the receptor, MCHR1. We have identified AMG 076 as an orally bioavailable potent and selective small molecule antagonist of MCHR1. In mouse models of obesity, AMG 076 caused a reduction in body weight gain in wild-type (MCHR1+/+) but not in knockout (MCHR1-/-) mice. The body weight reduction was associated with decreases in food intake and increases in energy expenditure. Importantly, we show that these MCHR1-dependent effects of AMG 076 were also reflected in improved metabolic phenotypes, increased glucose tolerance and insulin sensitivity. Preliminary data on effects of AMG 076 in obese cynomolgus monkeys are also presented.

Indexed as

AntagonistdiabetesMCHR1obesity

Identifiers

PMID25505557
PMCPMC4184568
OpenAlexW1996250873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.